8 Sources of evidence considered by the Committee

8 Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by Aberdeen Health Technology Assessment Group:

  • Robertson C, Cummins E, Fielding S et al., Aberdeen Health Technology Assessment Group, April 2015B.

The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to make written submissions. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I. Company:

  • Astellas

II. Professional/expert and patient/carer groups:

  • British Association of Urological Nurses

  • British Association of Urological Surgeons

  • British Uro-Oncology Group

  • Cancer Research UK

  • Prostate Cancer UK

  • Tackle Prostate Cancer

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians

III. Other consultees:

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Healthcare Improvement Scotland

  • Janssen

  • Institute of Cancer Research

  • MRC Clinical Trials Unit

  • National Collaborating Centre for Cancer

IV. Commentator organisations (did not provide written evidence and without the right of appeal):

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Healthcare Improvement Scotland

  • Janssen

  • Institute of Cancer Research

  • MRC Clinical Trials Unit

  • National Collaborating Centre for Cancer

C. The following individuals were selected from clinical expert and patient expert nominations from the consultees and commentators. They gave their expert personal view on enzalutamide by attending the initial Committee discussion and providing a written statement to the Committee. They were also invited to comment on the ACD.

  • Professor Noel Clarke, Professor of Urological Oncology, The Christie and Salford Royal Hospitals, Manchester, nominated by the British Association of Urological Surgeons – clinical expert

  • Dr Suneil Jain, Consultant Clinical Oncologist and Clinical Senior Lecturer, Queen's University Belfast, nominated by the Royal College of Physicians

  • Hugh Gunn, nominated by Tackle Prostate Cancer

  • Stuart Watson, nominated by Prostate Cancer UK – patient expert

D. Representatives from the following company attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Astellas

ISBN: 978-1-4731-1640-5

  • National Institute for Health and Care Excellence (NICE)